TY - JOUR T1 - Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 230 LP - 237 DO - 10.1124/dmd.112.047662 VL - 41 IS - 1 AU - Zhengping Wang AU - Jinfu Yang AU - Christopher Kirk AU - Ying Fang AU - Melissa Alsina AU - Ashraf Badros AU - Kyriakos Papadopoulos AU - Alvin Wong AU - Tina Woo AU - Darrin Bomba AU - Jin Li AU - Jeffrey R. Infante Y1 - 2013/01/01 UR - http://dmd.aspetjournals.org/content/41/1/230.abstract N2 - Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2–10 minutes, was evaluated in patients with solid tumors or MM. Metabolites of carfilzomib were characterized in patient plasma and urine samples. In vitro drug metabolism and DDI studies were conducted in human liver microsomes and hepatocytes. A clinical DDI study was conducted in patients with solid tumors to evaluate the effect of carfilzomib on CYP3A activity. Plasma concentrations of carfilzomib declined rapidly and in a biphasic manner after intravenous administration. The systemic half-life was short and the systemic clearance rate was higher than hepatic blood flow. Carfilzomib was cleared largely extrahepatically via peptidase cleavage and epoxide hydrolysis. Cytochrome P450–mediated metabolism played a minor role, suggesting that coadministration of P450 inhibitors or inducers is unlikely to change its PK profile. Carfilzomib showed direct and time-dependent inhibition of CYP3A in human liver microsome preparations and exposure to carfilzomib resulted in reductions in CYP3A and 1A2 gene expression in cultured human hepatocytes. However, administration of carfilzomib did not affect the PK of midazolam in patients with solid tumors, and there were no safety signals indicative of potential drug interactions. We conclude that the rapid systemic clearance and short half-life of carfilzomib limit clinically significant DDI. ER -